• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

PharmaJet partner touts interim safety results for needle-free COVID-19 vaccine

February 15, 2022 By Sean Whooley

PharmaJet Stratis
[Image from PharmaJet]
PharmaJet announced today that its partner, Technovalia, reported positive interim safety results from a needle-free COVID-19 vaccine trial.

Golden, Colorado-based PharmaJet’s needle-free injection systems are being studied with Covigen, a DNA-based vaccine developed by French-Thai pharmaceutical company BioNet-Asia in collaboration with Melbourne, Australia-based Technovalia. Enrollment for the trial began in June 2021.

The Phase 1 trial for the needle-free SARS-CoV-2 DNA vaccine in Australia had the purpose of assessing the safety and immunogenicity of two Covigen doses given one month apart to healthy volunteers aged 18 to 17 years old who had not yet received a COVID-19 vaccination. Interim results showed that Covigen was well-tolerated with no observed safety concerns, according to a news release.

Laurent Dapremont, CEO of Technovalia, said that Covigen represents the first plasmid-DNA vaccine to be tested in Australia, with a study group also set to assess Covigen as a booster dose on healthy subjects that are fully vaccinated.

“We welcome this positive news and are proud to be part of the Covigen vaccine development with Technovalia, BioNet, and their Australian partners,” PharmaJet President and CEO Chris Cappello said. “These results are consistent with data from other DNA and RNA based vaccines administered using the PharmaJet needle-free injection systems (NFIS). The PharmaJet NFIS is being used as the method of delivery on 20+ COVID vaccine development programs including the world’s first plasmid-based DNA vaccine recently receiving Emergency Use Authorization for COVID in India.”

Filed Under: Auto-injectors, Clinical Trials, Drug-Device Combinations, Featured, Pharmaceuticals Tagged With: coronavirus, COVID-19, PharmaJet

IN CASE YOU MISSED IT

  • Elixir Medical reports sustained durability with bioadaptor compared to Medtronic stent
  • Senseonics closes public offering, private placement with Abbott
  • Embecta eyes shift from insulin delivery to broader medical supplies focus
  • Medtronic earns expanded CE mark for Prevail paclitaxel-coated balloon
  • Sequel Med Tech to pair automated insulin delivery system with Abbott’s future dual glucose-ketone sensor

About Sean Whooley

Sean Whooley is an associate editor who mainly produces work for MassDevice, Medical Design & Outsourcing and Drug Delivery Business News. He received a bachelor's degree in multiplatform journalism from the University of Maryland, College Park. You can connect with him on LinkedIn or email him at swhooley@wtwhmedia.com.

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS